A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’xx Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181) (MK3475-181)